A Fusion Protein of Derp2 Allergen and Flagellin Suppresses Experimental Allergic Asthma.

CONCLUSIONS: The Derp2-FlaB fusion protein showed a strong anti-asthma immunomodulatory capacity, leading to the prevention of airway inflammatory responses in a murine disease model through the inhibition of Th2 responses. These findings suggest that the Derp2-FlaB fusion protein would be a promising vaccine candidate for HDM-mediated allergic asthma therapy. PMID: 30661317 [PubMed]

https://www.ncbi.nlm.nih.gov/pubmed/30661317?dopt=Abstract

Source: Allergy, Asthma and Immunology Research - January 22, 2019 Category: Allergy & Immunology Tags: Allergy Asthma Immunol Res Source Type: research